Plain-English translation of NCT06241326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study examining immunotherapy-based combination treatments in patients with hepatocellular carcinoma (liver cancer). Researchers are collecting data from thousands of Chinese patients — some who have already received these combination treatments and others who may receive them in the future — to understand how effective and safe these immune-based therapies are in everyday clinical care.
Liver cancer is a major health challenge in China, causing more than half of all new liver cancer cases and deaths worldwide. While immunotherapy-based combination treatments show promise, researchers need to study how well they work in real patients to help improve treatment options for liver cancer patients.
You likely qualify if…
You likely don't qualify if…
Depending on which group you join, you may either allow researchers to review your past medical records and treatment outcomes, or you may enroll to be followed prospectively as you receive treatment. The study will collect information about your background, liver cancer history, the treatments you receive, and how you respond to them over time. Most participation involves sharing your existing medical information rather than undergoing additional procedures.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Enrollment target
~11,000 participants
Started
March 2024
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xuehao Wang, professor
The First Affiliated Hospital with Nanjing Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.